Objective: To analyze the utility of total/free prostate–specific antigen (PSA) and age as predictors of the prostate volume in men with symptomatic benign prostatic hyperplasia (BPH) and no evidence of prostate cancer.Patients and Methods: Total and free serum PSA were determined in 681 patients with normal digital rectal examination and symptomatic BPH using the Hybritech method. Prostate volume was measured by transrectal ultrasound (TRUS). TRUS–guided biopsy was performed in 459 (67.4%) of the patients with a serum PSA >4.0 ng/ml.Results: The relationship with prostate volume was best described in a log linear fashion by free PSA (R2 = 0.367), total PSA (R2 = 0.264) and age (R2 = 0.017). Multiple linear regression demonstrates no significant influence of age. Free PSA was able to predict the individual TRUS prostate volume ±10% in 67% of the patients and ±20% in 91.2% and total PSA in 63 and 90.9%, respectively.Conclusion: Prostate volume is strongly related with free and total PSA. Both determinations would be able to predict the TRUS prostate volume ±20% in more than 90% of the patients.

Keywords:
Prostate volume, Total PSA, Free PSA, Age
1.
Boyle P, Gould AL, Roehrborn CG: Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta–analysis of randomized clinical trial. Urology 1996;48:398–405.
2.
Jacobsen SJ, Jacobsen DJ, Girman CJ, et al: Natural history of prostatism: Risk factors for acute urinary retention. J Urol 1997;158:481– 487.
3.
Roehrborn CG, McConnell JD, Lieber M, et al: Serum prostate–specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999;53:473–480.
4.
Oesterling JE, Jacobsen SJ, Chute CG, et al: Serum prostate–specific antigen in a community–based population of healthy men: Establishment of age–specific reference ranges. JAMA 1993;270:860–864.
5.
Benson MC, Wang IS, Pantuck A, et al: Prostate specific antigen density: A means of distinguish benign prostatic hypertrophy and prostate cancer. J Urol 1992;147:817–821.
6.
Bosch JL, Hop WC, Bangma CH, et al: Prostate specific antigen in a community–based sample of men without prostate cancer: Correlations with prostate volume, age, body mass index, and symptoms of prostatism. Prostate 1995;27:241–249.
7.
Aarnink RG, de la Rossete JJ, Huynen AL, et al: Standardized assessment to enhance the diagnostic value of prostate volume. II: Correlation with prostate–specific antigen levels. Prostate 1996;29:327–333.
8.
Di Dilverio F, Sciarra A, D’Eramo G, et al: Relationship among age, prostate–specific antigen, and prostate volume in men with lower urinary symptoms (LUTS) and in different groups of men with and without benign and malignant prostate diseases. Prostate 1998;36: 1–7.
9.
Roehrborn CG, Boyle P, Gould AL, et al: Serum prostate–specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999;53:581–589.
10.
Guess HA, Arrighi AM, Metter EJ, et al: Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostate hyperplasia. Prostate 1990;17:241–246.
11.
McConnell JD, Bruskewitz R, Walsh P, et al: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338:557–563.
12.
Roehrborn CG, Girman CJ, Rhodes T, et al: Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology 1997;49:548– 557.
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.